Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jan;33(1):75–81. doi: 10.1111/j.1365-2125.1992.tb04003.x

Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.

J D Holding 1, W E Lindup 1, C van Laer 1, G C Vreeburg 1, V Schilling 1, J A Wilson 1, P M Stell 1
PMCID: PMC1381202  PMID: 1540494

Abstract

1. A phase I trial of a cisplatin-albumin complex for the treatment of end-stage squamous cell carcinoma of the head and neck is reported. The complex was prepared by overnight incubation of cisplatin with human albumin at 37 degrees C. This resulted in more than 98% of the drug being bound to protein at the start of treatment. The patients were either unable to continue with or had refused conventional therapy with cisplatin. 2. The trial began at a dose of 100 mg cisplatin m-2 and was increased in 25 mg m-2 increments to 650 mg m-2. Despite the absence of the customary protective measures of pre-hydration and anti-emetic treatment no serious toxicity was encountered. 3. Unbound plasma platinum concentrations were lower than after conventional cisplatin treatment but total plasma platinum and tumour platinum concentrations were much higher. Urinary excretion of platinum was low and the incidence of nephrotoxicity was greatly diminished. Two responses were seen (one complete and one partial) in 38 patients treated and the median survival time was 109 days, compared with 151 days for patients treated conventionally with cisplatin and 56 days for untreated patients. 4. The complex is not as effective as conventional cisplatin therapy but is much less toxic, offers improved quality of life during treatment and may prove to be of benefit in patients who could not otherwise be treated.

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cerottini J. C., Isliker H. Transport d'agents cytostatiques par les protéines plasmatiques. I. Pénétration de la sérumalbumine dans les cellules tumorales. Eur J Cancer. 1967 Jun;3(2):111–124. doi: 10.1016/0014-2964(67)90033-3. [DOI] [PubMed] [Google Scholar]
  2. Cole W. C., Wolf W. Preparation and metabolism of a cisplatin/serum protein complex. Chem Biol Interact. 1980 May;30(2):223–235. doi: 10.1016/0009-2797(80)90128-3. [DOI] [PubMed] [Google Scholar]
  3. Cole W. C., Wolf W. Renal toxicity studies of protein-bound platinum(cis). Chem Biol Interact. 1981 Jun;35(3):341–348. doi: 10.1016/0009-2797(81)90009-0. [DOI] [PubMed] [Google Scholar]
  4. Gerlowski L. E., Jain R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986 May;31(3):288–305. doi: 10.1016/0026-2862(86)90018-x. [DOI] [PubMed] [Google Scholar]
  5. Gonias S. L., Pizzo S. V. Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule. J Biol Chem. 1983 May 10;258(9):5764–5769. [PubMed] [Google Scholar]
  6. Gullo J. J., Litterst C. L., Maguire P. J., Sikic B. I., Hoth D. F., Woolley P. V. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol. 1980;5(1):21–26. doi: 10.1007/BF00578558. [DOI] [PubMed] [Google Scholar]
  7. Hegedüs L., van der Vijgh W. J., Klein I., Kerpel-Fronius S., Pinedo H. M. Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chemother Pharmacol. 1987;20(3):211–212. doi: 10.1007/BF00570487. [DOI] [PubMed] [Google Scholar]
  8. Holding J. D., Lindup W. E., Bowdler D. A., Siodlak M. Z., Stell P. M. Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. Br J Clin Pharmacol. 1991 Aug;32(2):173–179. doi: 10.1111/j.1365-2125.1991.tb03878.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jacobs C., Bertino J. R., Goffinet D. R., Fee W. E., Goode R. L. 24-hour infusion of cis-platinum in head and neck cancers. Cancer. 1978 Nov;42(5):2135–2140. doi: 10.1002/1097-0142(197811)42:5<2135::aid-cncr2820420508>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  10. Juckett D. A., Rosenberg B. Actions of cis-diamminedichloroplatinum on cell surface nucleic acids in cancer cells as determined by cell electrophoresis techniques. Cancer Res. 1982 Sep;42(9):3565–3573. [PubMed] [Google Scholar]
  11. Katz J., Bonorris G., Golden S., Sellers A. L. Extravascular albumin mass and exchange in rat tissues. Clin Sci. 1970 Dec;39(6):705–724. doi: 10.1042/cs0390705. [DOI] [PubMed] [Google Scholar]
  12. Katz J., Bonorris G., Sellers A. L. Extravascular albumin in human tissues. Clin Sci. 1970 Dec;39(6):725–729. doi: 10.1042/cs0390725. [DOI] [PubMed] [Google Scholar]
  13. Litterst C. L., Gram T. E., Dedrick R. L., Leroy A. F., Guarino A. M. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res. 1976 Jul;36(7 Pt 1):2340–2344. [PubMed] [Google Scholar]
  14. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  15. Morimoto C. Cytochemical study on uptake of exogenous peroxidase by Vx2 carcinoma cells transplanted into the rabbit. J Natl Cancer Inst. 1978 Nov;61(5):1215–1220. doi: 10.1093/jnci/61.5.1215. [DOI] [PubMed] [Google Scholar]
  16. Nanji A. A., Stewart D. J., Mikhael N. Z. Relationship between urine beta-2-microglobulin and platinum levels during cisplatin treatment. Clin Biochem. 1988 Jan;21(1):69–71. doi: 10.1016/s0009-9120(88)80115-2. [DOI] [PubMed] [Google Scholar]
  17. Posner M. R., Ferrari L., Belliveau J. F., Cummings F. J., Wiemann M. C., O'Rourke A., Weitberg A. B., Calabresi P. A phase I trial of continuous infusion cisplatin. Cancer. 1987 Jan 1;59(1):15–18. doi: 10.1002/1097-0142(19870101)59:1<15::aid-cncr2820590107>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  18. RYSER H., AUB J. C., CAULFIELD J. B. Studies on protein uptake by isolated tumor cells. II. Quantitative data on the adsorption and uptake of I-131-serum albumin by Ehrlich ascites tumor cells. J Cell Biol. 1962 Dec;15:437–449. doi: 10.1083/jcb.15.3.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Reece P. A., Stafford I., Abbott R. L., Anderson C., Denham J., Freeman S., Morris R. G., Gill P. G., Olweny C. L. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol. 1989 Feb;7(2):270–275. doi: 10.1200/JCO.1989.7.2.270. [DOI] [PubMed] [Google Scholar]
  20. Sorenson C. M., Barry M. A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 1990 May 2;82(9):749–755. doi: 10.1093/jnci/82.9.749. [DOI] [PubMed] [Google Scholar]
  21. Takahashi K., Seki T., Nishikawa K., Minamide S., Iwabuchi M., Ono M., Nagamine S., Horinishi H. Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn J Cancer Res. 1985 Jan;76(1):68–74. [PubMed] [Google Scholar]
  22. Terheggen P. M., Emondt J. Y., Floot B. G., Dijkman R., Schrier P. I., den Engelse L., Begg A. C. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 1990 Jun 15;50(12):3556–3561. [PubMed] [Google Scholar]
  23. Vermorken J. B., van der Vijgh W. J., Klein I., Gall H. E., van Groeningen C. J., Hart G. A., Pinedo H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther. 1986 Feb;39(2):136–144. doi: 10.1038/clpt.1986.24. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES